As­traZeneca con­tin­ues to build out its pres­ence in Chi­na with new COPD drug man­u­fac­tur­ing site

As­traZeneca has been grow­ing its pres­ence in Chi­na over the past sev­er­al years, and the phar­ma’s lat­est ven­ture in the coun­try will see it es­tab­lish a man­u­fac­tur­ing process for COPD treat­ments.

Ac­cord­ing to a press re­lease, trans­lat­ed from Chi­nese, As­traZeneca of­fi­cial­ly an­nounced it will ex­pand its in­vest­ment in Chi­na and plans to spend some cash to con­struct a pro­duc­tion and sup­ply base as well, as a re­gion­al head­quar­ters in the port city of Qing­dao, Shan­dong in east­ern Chi­na. Qing­dao will al­so be home to an in­no­va­tion cen­ter fo­cused on rare dis­eases, a life sci­ence in­no­va­tion park and an in­dus­tri­al fund.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.